A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, 3-arm Phase 2 study to evaluate the efficacy and safety of
SHR-1210 alone or with SHR-1020 versus physician's choice chemotherapy in recurrent or
metastatic cervical cancer patients. All enrolled patients will be randomly divided into 3
groups and receive treatment until disease progression, intolerable toxicity，any criterion
for stopping the study drug or SHR-1210 treatment for up to 2 years.